News and Trends 8 Dec 2022 DNA repair mechanism study could boost cancer treatment A better understanding of the mechanisms involved in DNA repair may pave the way for developing inhibitors to improve the effectiveness of radiation therapy. Nucleotide excision repair (NER) is a critical DNA repair pathway that plays a key role in maintaining transcription and genome integrity by removing bulky DNA lesions. The key steps in the […] December 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 Apogee Therapeutics raises $169M to tackle immunological and inflammatory disorders Apogee Therapeutics, LLC, a biotech company advancing novel, potentially best-in-class therapies to address immunological and inflammatory disorders, has announced the closing of a $149 million Series B financing. Proceeds will be used to support Apogee’s plans to advance its lead pipeline program into the clinic in 2023 and expand the leadership, scientific, and clinical teams […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 PacBio and Boston Children’s Hospital to study genome to benefit patients PacBio, a developer of sequencing solutions, says its HiFi sequencing technology will be used in a pilot project for the Children’s Rare Disease Cohorts Initiative (CRDC) at Boston Children’s Hospital in the U.S. Boston Children’s Hospital researchers will use HiFi whole-genome sequencing (HiFi WGS) for the purpose of investigating genetic and epigenetic variants associated with […] December 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 Rani Therapeutics reveals results from phase 1 osteoporosis study Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, has announced topline results from part 2 (the repeat-dose portion) of the phase 1 study of RT-102, the RaniPill GO capsule containing a proprietary formulation of human parathyroid hormone (1-34) analog (PTH) being developed for the treatment of […] December 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 FDA clears insulin pen medical device BIOCORP, a French company specialized in the design, development, and manufacturing of innovative medical devices, has received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market Mallya, its smart medical device that connects insulin pens. Eric Dessertenne, CEO of BIOCORP, said: “This approval is a major achievement for BIOCORP and all of […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 Entact Bio launches with $81M to develop precision medicines Entact Bio has raised $81 million in series A financing to advance its proprietary Encompass platform for developing enhancement-targeting chimeric (ENTAC) molecules. The round was co-led by Qiming Venture Partners USA and venBio Partners, with participation by new investors Abingworth, Brandon Capital, Janus Henderson Investors, Logos Capital, Surveyor Capital (a Citadel company), and WEHI (Walter […] December 6, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 Avalon BioVentures to invest in early-stage biotech L.P., a venture capital firm dedicated to early-stage biomedical innovation, has closed its first venture fund, ABV1, with $135 million in funding from new and existing institutional investors. Avalon BioVentures emerged from Avalon Ventures’ shared life-science/high-tech investing funds as a life-science only fund and will continue to leverage Avalon’s team and company accelerator to create, […] December 6, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 Pictor receives $5M in funding for Covid antibody test and human and animal portfolios Pictor, a global leader in immunodiagnostics, has announced a $5 million funding round to help accelerate pipeline product development projects. The company will also use the funding for market development activities within Australia and New Zealand, the U.S. and Europe for its human health and animal health portfolios. This follows a June funding round raising […] December 6, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 Positive results from BioAge muscle atrophy trial BioAge Labs, Inc. has announced positive phase 1b clinical data for BGE-105, a highly selective, potent, orally available small-molecule agonist of the apelin receptor APJ. BGE-105 treatment resulted in statistically significant prevention of muscle atrophy relative to placebo in healthy volunteers aged 65 or older after 10 days of strict bed rest. Muscle atrophy—loss of […] December 6, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 New company Liminatus Pharma Inc to develop three cancer treatments Clinical-stage biopharma company Liminatus Pharma LLC and Iris Acquisition Corp, a publicly traded special purpose acquisition company formed for the purpose of acquiring or merging with one or more businesses, announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed Liminatus Pharma, Inc.. The […] December 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 MaxCyte and Curamys sign cell and gene therapies agreement MaxCyte, Inc. and Curamys have announced the signing of a strategic platform license. MaxCyte is a cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support cell-based research. Curamys is a South Korean biotechnology company developing cell and gene therapy using cell fusion technology […] December 5, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 5 Dec 2022 Interview: why the recently approved fecal microbiome product is causing a rumble The news last week of the FDA approving Ferring Pharmaceuticals’ first fecal microbiome product, Rebyota, caused quite a stir in the field. The news was described as a huge step, a giant leap forward and simply fantastic. Paul Feurstadt is the director of non-inflammatory bowel disease research at the Medical Research Center of Connecticut. He also […] December 5, 2022 - 5 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email